Supreme Court Upholds Conviction as Husband Failed to Explain Wife’s Death in Matrimonial Home || Supreme Court: Crime Scene Re-Enactment Does Not Always Violate Right Against Self-Incrimination || Supreme Court: Cognizance Taken Without Hearing Accused under BNSS Section 223 is Void Ab Initio || Supreme Court Upholds Will in Sister’s Favour, Says Excluding Natural Heirs is Not Suspicious || Delhi HC: Absence of Public Witnesses and Videography in NDPS Recovery Relevant for Bail Decisions || Raj HC Initiates Suo Motu Cognizance Over Severe Water Crisis in Jodhpur, Issues Interim Directions || Del HC: Courts Cannot Direct, Monitor Inquiry Into Police Delay in Investigation After Bail Decision || Supreme Court: After the BNSS, a Pre-Cognizance Hearing is Mandatory in PMLA Cases || SC: Landowners Cannot be Forced to Waive Statutory Compensation to Claim Other Benefits || Supreme Court: Banks are Lenient With Big Borrowers But Strict With Ordinary Loan Applicants

Merck Sharp & Dohme Corporation & Anr. v. Glenmark Pharmaceuticals Ltd. - (High Court of Delhi) (07 Oct 2015)

Delhi High Court rules in favour of Merck for its diabetes drug

Intellectual Property Rights

The Delhi High Court restrained Glenmark from selling any drug containing Sitagliptin or its derivate. Sitagliptin is the active ingredient used in ‘Januvia’, Merck’s once-daily pill used to lower blood sugar levels in people with Type II diabetes. It had claimed that Glenmark had infringed its patent in the specific chemical. The court dismissed contentions that Glenmark’s product, ‘Zita’, was different from Merck’s product.

Relevant : Read the decision in Merck Sharp & Dohme Corporation v. Glenmark Pharmaceuticals Ltd.

Tags : GLENMARK MERCK PATENT DIABETES

Share :